Roth Boosts PT on Concert Pharma (CNCE) to $22 Following; Deuterium Platform, Partnerships Will Bolster Gains
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
May 8, 2015 7:00 AM EDTConference Call Scheduled Today at 8:30 a.m. EDT
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2015.
Concert ended the first quarter with a strong balance sheet and the financial resources to continue advancing our portfolio of product candidates, said Roger Tung,... More
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
May 7, 2015 4:05 PM EDTPhase 1 Results Support Further Evaluation of JZP-386
DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)... More
